Comfort and Performance of Intermittent Catheter Clinical Trial
Official title:
A Multi-centre Clinical Investigation to Assess the Performance of GentleCath™ Glide Intermittent Catheters
| Verified date | December 2022 |
| Source | ConvaTec Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To evaluate the performance of GentleCath Glide™ Intermittent Catheters
| Status | Completed |
| Enrollment | 39 |
| Est. completion date | January 10, 2018 |
| Est. primary completion date | January 10, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Subjects of 18 years old and above who require intermittent bladder drainage may be recruited into the study - Subjects must be willing and able to provide written informed consent - Subjects may be either inpatients or outpatients but must all be capable of completing a patient diary card to record study data - Subjects must currently use intermittent catheters and have been using intermittent catheters for the last six months - Patients who self-catheterise at least three times per day - Able to attend final assessment visit at day 14 Exclusion Criteria - Subjects who require intermittent catheterisation to administer irrigation or instillation. - Subjects who are presently participating in another clinical trial. - Subjects exhibiting any other medical condition which, according to the investigator, justifies the subject's exclusion from the study - Subjects with known sensitivity to the device components |
| Country | Name | City | State |
|---|---|---|---|
| Poland | Specjalistyczny Gabinet Lekarski | Rzeszow |
| Lead Sponsor | Collaborator |
|---|---|
| ConvaTec Inc. |
Poland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Performance/Ease of Use | Performance and ease of use will be assessed by both the patient and Investigator. The data will be collected via a questionnaire. The responses will be on a 1 to 5 scale with 1 disagreeing with the statement and 5 agreeing with the statement | 14 Days | |
| Primary | Ease of Removal | Ease of removal will be assessed by both the patient and Investigator. The data will be collected via a questionnaire. The responses will be on a 1 to 5 scale with 1 disagreeing with the statement and 5 agreeing with the statement | 14 Days | |
| Primary | Residue Acceptability | Residue acceptability will be assessed by both the patient and Investigator. The data will be collected via a questionnaire. The responses will be on a 1 to 5 scale with 1 disagreeing with the statement and 5 agreeing with the statement | 14 Days |